Glioblastoma Multiforme Clinical Trial
Official title:
Phase 2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab in Adults With Recurrent or Progressive Glioblastoma Following a Bevacizumab-Containing Regimen
The purpose of this study is to evaluate the safety, maximum tolerated dose (MTD), and efficacy of TPI 287 in combination with Avastin (bevacizumab) in subjects who have glioblastoma multiforme (GBM) that has progressed following prior radiation and temozolomide (TMZ) therapy and that has progressed following prior bevacizumab therapy.
This multi-center trial is a phase 2, dose-escalation study of the safety, tolerability
(MTD), and efficacy of TPI 287 in combination with bevacizumab in subjects who have GBM that
has progressed following prior radiation and TMZ therapy and that has progressed following
prior bevacizumab therapy.
All subjects will be administered TPI 287 as an intravenous (IV) infusion (target duration of
1 hour) once every 3 weeks (Days 1 and 22 of a 42-day cycle) and bevacizumab as a 30 to 90
minute IV infusion once every 2 weeks (Days 1, 15, and 29 of the 42-day cycle). The
subsequent cycle will start 3 weeks after the last TPI 287 infusion and 2 weeks after the
last bevacizumab infusion, maintaining the once every 3 week and once every 2 week schedule,
respectively.
The dose of TPI 287 will be escalated in sequential dose cohorts of 3 to 6 subjects, while
the dose of bevacizumab remains constant (10 mg/kg). The initial cohort of 3 subjects will be
treated at a TPI 287 dose of 140 mg/m2 (dose level 0). The next dose level will be 160 mg/m2
(dose level 1). Subsequent dose levels will be increased in increments of 10 mg/m2 (i.e.,
dose level 2 = 170 mg/m2, dose level 3 = 180 mg/m2, etc.). If dose de-escalation below the
starting dose level is required, dose levels of 130 and 120 mg/m2 will be used. Twelve (12)
to 18 subjects are planned for enrollment during the dose escalation phase, depending on the
number of subjects that experience dose limiting toxicities (DLTs).
Once the MTD is identified, 6 additional subjects will be enrolled at the MTD (for a total of
12) to better characterize the toxicity profile at this level.
Dose modifications and delays will be required as described in the protocol. Subjects may
continue on treatment unless they meet one or more of the discontinuation criteria outlined
in the protocol. Subjects who are discontinued prior to completing Cycle 1 for any reason
other than toxicity will be replaced.
Adverse events (AEs) and concomitant medications will be monitored throughout the study.
Subjects will be given a diary to record any AEs or concomitant medications taken between
visits. Additional safety evaluations will include physical examination (including neurologic
examination), Karnofsky performance status (KPS), weight (body surface area, BSA), vital
signs, hematology, serum chemistry, and urinalysis.
Efficacy evaluations will include magnetic resonance imaging [MRI, including both pre and
post-gadolinium T1-weighted scans and T2/fluid attenuated inversion recovery (FLAIR) images],
corticosteroid usage, and neurologic status (as measured by neurologic exam and KPS).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05023551 -
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
|
Early Phase 1 | |
Recruiting |
NCT06059690 -
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
|
Phase 1/Phase 2 | |
Recruiting |
NCT04116411 -
A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients
|
Phase 2 | |
Terminated |
NCT01902771 -
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT02386826 -
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00038493 -
Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Withdrawn |
NCT03980249 -
Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells
|
Early Phase 1 | |
Recruiting |
NCT01923922 -
CT Perfusion in the Prognostication of Cerebral High Grade Glioma
|
N/A | |
Completed |
NCT01956734 -
Virus DNX2401 and Temozolomide in Recurrent Glioblastoma
|
Phase 1 | |
Completed |
NCT01402063 -
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation
|
Phase 2 | |
Completed |
NCT01301430 -
Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.
|
Phase 1/Phase 2 | |
Suspended |
NCT01386710 -
Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00995007 -
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
|
Phase 2 | |
Terminated |
NCT00990496 -
A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)
|
Phase 1 | |
Terminated |
NCT01044966 -
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
Completed |
NCT00402116 -
Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00504660 -
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
|
Phase 2 | |
Recruiting |
NCT05366179 -
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
|
Phase 1 |